King’s College London’s pioneering research in artificial intelligence & data analytics will strengthen Moon Surgical’s innovative Maestro platform
Paris, London & San Francisco – March 23rd, 2021. Moon Surgical and King’s College London, School of Biomedical Engineering & Imaging Sciences, today announce a new strategic partnership to develop Machine Learning applications for Computer-Assisted Surgery, which aims to strengthen surgical artificial intelligence (AI), data and analytics, and accelerate translation from King’s College London research into clinical usage.
King’s College London (“King’s”) has pioneered research in machine learning in order to provide new capabilities and solutions for surgery through interventional imaging computing.
From King’s, the collaboration will be led by Tom Vercauteren, Professor of Interventional Image Computing, who is also part of the new Department of Surgical & Interventional Engineering.
Researchers from both teams will work together to build, annotate and leverage surgical datasets in order to develop robotic surgeon-enhancing features for Moon Surgical’s Maestro platform.
“Our approach senses, in real-time, an augmented surgeon at the patient’s side, giving us a never before-explored opportunity of gathering the actual movements and intentions of the surgeon in unique datasets,” said Anne Osdoit, Chief Executive Officer of Moon Surgical. “We are very excited to be working with world-renowned surgical and interventional researchers from King’s College London to explore how new concepts in machine learning can yield increased safety, efficiency, transparency and ease of use of our Maestro platform.”
Professor Seb Ourselin, Head of the School of Biomedical Engineering & Imaging Sciences, said this collaboration is a great step towards the continuous development of surgical and interventional engineering, a key strategic research area of the School.
“Working closely with early-phase companies such as Moon Surgical is core to our mission at King’s College London to bring at pace healthcare engineering innovations into the clinic. I am very excited by this new partnership, which will bring our machine learning expertise in surgery into the pioneering Maestro platform.”
Professor Vercauteren said: “Our team has a vision for the delivery of consistent, data-driven surgical procedures. With our powerful setup, perfectly integrated into clinical care, we will be able to streamline algorithms from the computational stage to the operating room. We look forward to applying our framework with Moon Surgical so that our digital technologies enable enhanced surgery in an accessible, safe and transformative manner.”
About Moon Surgical
Moon Surgical, based in Paris, France and San Carlos, California, is a pre-clinical stage medical device company established by Sofinnova MD Start III in 2020. It is focused on the development of a new platform dedicated to surgical assistance. www.moonsurgical.com
About King’s College London
King's College London is one of the top 10 UK universities in the world (QS World University Rankings, 2018/19) and among the oldest in England. King’s has more than 31,000 students (including more than 12,800 postgraduates) from some 150 countries worldwide, and some 8,500 staff.
King's has an outstanding reputation for world-class teaching and cutting-edge research. In the 2014 Research Excellence Framework (REF), eighty-four per cent of research at King’s was deemed ‘world-leading’ or ‘internationally excellent’ (3* and 4*).
Since our foundation, King’s students and staff have dedicated themselves in the service of society. King’s will continue to focus on world-leading education, research and service, and will have an increasingly proactive role to play in a more interconnected, complex world. Visit our website to find out more about Vision 2029, King’s strategic vision for the next years to 2029, which will be the 200th anniversary of the founding of the university.
World-changing ideas. Life-changing impact: https://www.kcl.ac.uk/news
Anne Osdoit, CEO, Moon Surgical
+33 (0) 6 60 42 28 31
King’s College London
+44 (0) 20 7848 3202
RooneyPartners LLC, Kate Barrette
+1 212 223 0561
Strategies Image, Anne Rein
+33 (0) 6 03 35 92 05
CinCor Pharma announces positive topline data for Phase 2 BrigHtn trial evaluating baxdrostat, its selective aldosterone synthase inhibitor, in treatment-resistant hypertension
F2G announces $70 million financing to advance development and commercialization of new antifungal agent olorofim
Noema Pharma announces recruitment of first patient in Orpheus Phase 2b Study of PDE10A inhibitor gemlapodect in adults with childhood onset fluency disorder
CinCor Pharma announces last patient randomized in Phase 2 HALO Trial and initiation of long-term extension study for Baxdrostat, a selective aldosterone synthase inhibitor, in uncontrolled hypertension
ReCor Medical and Otsuka Medical Devices announce primary endpoint met in the RADIANCE II U.S. pivotal trial of the Paradise™ System for the treatment of hypertension